Dr. Rachel Rubin

Remember, no advisory panel to put the estrogen label on.

And then the FDA, because of that advisory panel, said do this five-year-long study, prove this, this, this, and this, and we'll remove the label.

So what happened?

The companies came together, the people came together, and they did a five-year study called the Traverse Trial.

The Traverse Trial came out, and within just a couple of, you know, months or, you know, with the Traverse Trial out, they removed the label with no advisory panel.

And there was no controversy.

There was no one cared.

They said they did the study, they removed it, there was no advisory panel, fine, the label is now gone.

estrogen, right?

They remove the label and there is some pushback of, oh, they didn't do enough to like make sure it was the right move.

But the label never should have been there in the first place, right?

No one, there's no data to say that what the label said warrants being on a label.

They didn't remove the information.

The data is still there, right?

The relative risk and the absolute risk and what the women, it's all still in the label.

Read the label, people.

Once they update it, it's all still there.

And so people getting, this is just saying hormone therapy is a nuanced discussion that you should have with your doctor who should know the data and we should be teaching in medical schools and residencies.

And it shouldn't just be your OBGYN, it should be your urologist, your neurologist, your orthopedic surgeon, every doctor, your primary care doctor who takes care of women, every doctor who takes care of women should know about hormone therapy and be able to counsel appropriately.

That's all we're asking.